Tests magnetic stimulation to ease slowness of movement in Parkinson's disease
Tests magnetic brain stimulation against a sham in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: prTMS as an Intervention for Bradykinesia in Parkinson's Disease
Key facts
- Where
- Hvidovre, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07397377, who can take part
Where in Denmark
- DRCMRHvidovre, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Danish Research Centre for Magnetic Resonance
- Trial code
- NCT07397377
- Record updated
- 9 February 2026
- Original description
This study investigates the use of patterned repetitive transcranial magnetic stimulation (prTMS) as an intervention for bradykinesia in Parkinson's Disease (PD). More specifically, the study aims to determine whether prTMS over the supplementary motor area (SMA) can reduce severity of bradykinesia in PD patients. This approach may open for more targeted and effective treatment of bradykinesia in PD.Read full original descriptionShow less
Enhancing rTMS Effects Through a State-Dependent Approach - An Intervention for Bradykinesia in Parkinson's Disease
This study investigates the use of patterned repetitive transcranial magnetic stimulation (prTMS) as an intervention for bradykinesia in Parkinson's Disease (PD). More specifically, the study aims to determine whether prTMS over the supplementary motor area (SMA) can reduce severity of bradykinesia in PD patients. This approach may open for more targeted and effective treatment of bradykinesia in PD.
Inclusion: Above 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society; Clinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent.
Exclusion: Psychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin); History of neurological disease other than PD. Past or present mental illness. History of epilepsy/conditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS); Close relatives suffering from epilepsy/conditions associated with increased risk of seizures; Contraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial; Frequent benzodiazepine or opioid use defined as more than once per week on a regular basis; Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.